Adebrelimab with Chemo and Radiation for Stomach Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called adebrelimab along with chemotherapy and radiation before surgery for stomach or gastroesophageal junction cancer that has spread locally or has limited spread. It aims to see if this combination can help make the tumor removable and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adenocarcinoma (a common type) of the stomach or the area where the stomach meets the esophagus.
- Your cancer is locally advanced or has limited spread, and doctors believe it can be removed with surgery.
- You do not have cancer cells in the lining of the abdominal cavity (peritoneal metastasis).
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges as determined by standard lab tests.
- You are between 18 and 80 years old, able to give informed consent, and not pregnant or breastfeeding.
- You have not had major surgery or a severe injury in the last 4 weeks, and you have no active autoimmune disease or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
This trial tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (capecitabine and oxaliplatin) for people with stomach cancer or cancer where the stomach meets the esophagus. It aims to see if this combination is safe and effective for patients who have not had prior treatment for advanced disease.
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.